Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis

Medicine
Wen-Xiu XinPing Huang

Abstract

To assess the association between hypoglycemic agents and prognosis of lung cancer patients with diabetes. A comprehensive literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library until May 2017. The search yielded 2593 unique citations, of which 18 articles met inclusion criteria. The hazard ratios (HRs) and 95% confidence intervals (95% CIs) were calculated by a fixed-effects or random-effects model. The pooled HRs favoring metformin users were 0.77 for overall survival (OS) (n = 15, 95% CI: 0.68-0.86) and 0.50 for disease-free survival (n = 5, 95% CI: 0.39-0.64). One study assessed the relationship between metformin and cancer-specific survival (CSS), reporting no significant results. No significant association between insulin and OS (n = 2, HR: 0.95, 95% CI: 0.79-1.13) or CSS (n = 2, HR: 1.03, 95% CI: 0.76-1.41) was noted. One study evaluated association of sulfonylureas with lung cancer survival and reported no clinical benefit (HR: 1.10, 95% CI: 0.87-1.40). One study reported no association of thiazolidinediones with lung cancer survival (HR: 1.04, 95% CI: 0.65-1.66). This meta-analysis demonstrated that metformin exposure might improve survival outcomes in lung cancer patients with diabetes.

References

Feb 12, 2002·Statistics in Medicine·Hans C van HouwelingenTheo Stijnen
Jun 19, 2002·The Journal of Surgical Research·Clifford Ko, Saima Chaudhry
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Aug 23, 2003·Biostatistics·J Copas, J Q Shi
Jul 1, 2005·The New England Journal of Medicine·James L Mulshine, Daniel C Sullivan
Jul 1, 2009·The International Journal of Biochemistry & Cell Biology·Jie ZhouChenguang Wang
Mar 11, 2010·Journal of Experimental & Clinical Cancer Research : CR·Takayuki YoshizakiToshikatsu Okumura
Dec 3, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chia-Hsuin ChangK Arnold Chan
Jan 4, 2012·Annals of the New York Academy of Sciences·Emily Jane Gallagher, Derek LeRoith
Sep 18, 2012·BMC Cancer·Peter J MazzoneMadhu Sasidhar
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Nov 23, 2013·Diabetes Research and Clinical Practice·Chin-Hsiao Tseng
Mar 29, 2014·PloS One·Sorin IoacaraMichael Roden
Jul 24, 2014·Journal of the American Medical Informatics Association : JAMIA·Hua XuJoshua C Denny
Dec 19, 2014·American Journal of Respiratory and Critical Care Medicine·Jenny J LinJuan P Wisnivesky
May 20, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Fanming KongYingjie Jia
Jun 13, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·T XuF Zhang
Oct 16, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R-H TianH-L Ji
Feb 11, 2016·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Krista C J WinkEsther G C Troost
Mar 15, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Úna C Mc MenaminLiam M Murray
Oct 23, 2016·Oncotarget·Carla MicucciAlfonso Catalano
May 10, 2016·The Journal of Thoracic and Cardiovascular Surgery·Robert A MedairosChristopher W Seder
Apr 6, 2017·International Journal of Cancer. Journal International Du Cancer·Jie LinKangmin Zhu

❮ Previous
Next ❯

Citations

Oct 8, 2019·Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·Guoshu BiHong Fan
Nov 2, 2019·Endocrine, Metabolic & Immune Disorders Drug Targets·Silvia SciannimanicoVincenzo Triggiani
Oct 18, 2019·Frontiers in Endocrinology·Hong YuYongxi Song
Sep 23, 2018·International Journal of Molecular Sciences·Hans-Juergen Schulten
Mar 12, 2020·International Journal of Environmental Research and Public Health·Edvardas DanilaGiedrė Smailytė
Dec 3, 2020·British Journal of Cancer·Suzan BrancherTrond-Eirik Strand

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

Review Manager
Stata

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.